Orofacial pain in oncology: use of a new analgesic peptide tafalgin

In patients with head and neck tumors severe pain is more common than in patients with malignant neoplasms of other locations. At a third of patients, pain is the first characteristic of the disease, and after diagnosis, one half of the patients are already having pain syndrome. Аntitumor treatment often not only bring relief, but can intensify pain, which can reduce wish to treated. Part of cancer survivor continue to experience. Thus, orofacial pain syndrome should be share depending on the mechanism of appearence and tactics of treatment on three periods: pain at the stage of diagnosis, then pain syndrome in process antitumor therapy and pain in remission. It is actually if it necessary to prescribe opioid analgesics, especially for a long time. Intensity of orofacial pain syndrome is usually strong and often need to prescribe opioid analgesics. Option to opioid analgesics may be a representative of a new group of analgetics – peptide analgesics – tafalgin. The mechanism of action is due to highly selective agonism to the m1-opioid receptors. The presented clinical example demonstrates the good analgesic effect of tafalgin and the possibility use as option to analgesics of the second stage of pain management.

1. van den Beuken–van Everdingen M.H., Hochstenbach L.M., Joosten E.A. et al. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain ymptom Manage 2016;51(6):1070–90. DOI: 10.1016/j.jpainsymman.2015.12.340

2. van den Beuken–van Everdingen M.H., de Rijke J.M., Kessels A.G. et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18(9):1437–49. DOI: 10.1093/annonc/mdm056

3. Epstein J.B., Thariat J., Bensadoun R.-J. et al. Oral complications of cancer and cancer therapy. CA Cancer J Clin 2012;62:400–22. DOI: 10.3322/caac.21157

4. Epstein J.B., Wilkie D.J., Fischer D.J. et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol 2009;1:26. DOI: 10.1186/1758-3284-1-26

5. Romero-Reyes M., Salvemini D. Cancer and orofacial pain. Med Oral Patol Oral Cir Bucal 20161;21(6):665–71. DOI: 10.4317/medoral.21515

6. Schmidt B.L. What pain tells us about cancer. Pain 2015;156(1):32–4. DOI: 10.1097/j.pain.0000000000000099

7. Epstein J.B., Elad S., Eliav E. et al. Orofacial pain in cancer: part II – clinical perspectives and management. J Dent Res 2007;86(6):506–18. DOI: 10.1177/154405910708600605

8. Benoliel R., Epstein J., Eliav E. et al. Orofacial pain in cancer: part I – mechanisms. J Dent Res 2007;86(6):491–505. DOI: 10.1177/154405910708600

9. Johnston M., Yu E., Kim J. Perineural invasion and spread in head and neck cancer. Expert Rev Anticancer Ther 2012;12(3):359–71. DOI: 10.1586/era.12.9

10. Binmadi N.O., Basile J.R. Perineural invasion in oral squamous cell carcinoma: a discussion of significance and review of the literature. Oral Oncol 2011;47(11):1005–10. DOI: 10.1016/j.oraloncology.2011.08.002

11. Connelly S.T., Schmidt B.L. Evaluation of pain in patients with oral squamous cell carcinoma. J Pain 2004;5(9):505–10. DOI: 10.1016/j.jpain.2004.09.002

12. Clinical Guidelines “Chronic pain syndrome in adult patients in need of palliative care” (revised in 2023). (In Russ.). Available at: https://cr.minzdrav.gov.ru/recomend/400_2.

13. Recommendations on RUSSCO supportive and accompanying therapy (revised in 2022, with amendments in 2023). (In Russ.). Available at: https://rosoncoweb.ru/standarts/suptherapy/.

14. von Gunten C.F. Pathophysiology of pain in cancer. J Pediatr Hematol Oncol 2011;33(1):12–8 DOI: 10.1097/MPH.0b013e31821218a7.

15. Campos M.I., Campos C.N., Aarestrup F.M. Aarestrup B.J. Oral mucositis in cancer treatment: natural history, prevention and treatment. Mol Clin Oncol 2014;2(3):337–40. DOI: 10.3892/mco.2014.253

16. Brook I. Early side effects of radiation treatment for head and neck cancer. Cancer Radiother 2021;25(5):507–13. DOI: 10.1016/j.canrad.2021.02.001

17. National Guidelines for Palliative care in Oncology. Moscow: P.A. Herzen Moscow State Medical Institute – branch of the “NMIC of Radiology” of the Ministry of Health of Russia, 2022. 514 p.

18. Chen S.-C. Oral dysfunction in patients with head and neck cancer: a systematic review. J Nurs Res 27(6):58. DOI:10.1097/jnr.000000000000036

19. Gevorkov A.R., Boyko A.V., Bolotina L.V. et al. Results of implementation of a program of individual support of chemoradiation therapy in patients with head and neck tumors. Opukholi golovy i shei = Head and Neck Tumors 2020;10(4):60–73. (In Russ.). DOI: 10.17650/2222-1468-2020-10-4-60-73

20. Gevorkov A.R., Boyko A.V., Kaprin A.D. Stereotactic radiation therapy (SBRT) in patients with head and neck tumors. The current state of the problem. Medical Radiology and Radiation Safety 2022;67(1):65–76. (In Russ.). DOI: 10.12737/1024-6177-2022-67-1-65-76

21. Kaprin A.D., Abuzarova G.R., Nevzorova D.V. et al. New WHO guidelines for cancer pain in adults and adolescents. Research and Practical Medicine Journal 2021;8(2):90–108. (In Russ.). DOI: 10.17709/2410-1893-2021-8-2-9

22. Gevorkov A.R., Boykо A.V., Bolotinа L.V., Shashkov S.V. Basic principles of managing radiation and drug induced mucositis and dermatitis for oropharyngeal squamouscell carcinoma. Opukholi golovy i shei = Head and Neck Tumors 2016;6(3):12–21. (In Russ.). DOI: https://orcid.org/10.17650/2222-1468-2016-6-3-22-32

23. Epstein J.B., Hong C., Logan R.M. et al. A systematic review of orofacial pain in patients receiving cancer therapy. Support Care Cancer 2010;18(8):1023–31. DOI: 10.1007/s00520-010-0897-7

24. Taylor J.C., Terrell J.E., Ronis D.L. et al. Disability in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:764–9. DOI: 10.1001/archotol.130.6.76

25. Thompson T.L., Pagedar N.A., Karnell L.H., Funk G.F. Factors associated with mortality in 2-year survivors of head and neck cancer. Arch Otolaryngol 2011;137(11):1100–5. DOI: 10.1001/archoto.2011.179

26. Yang X., Yang X., Wang W. et al. Primary first bite syndrome of the parotid gland: case report and literature review. Ear Nose Throat J 2022;101(7):468–73. DOI: 10.1177/0145561320962584

27. Ghosh A., Mirza N. First bite syndrome: our experience with intraparotid injections with botulinum toxin type A. Laryngoscope 2016;126(1):104–7. DOI: 10.1002/lary.25571

28. Linkov G., Morris L.G., Shah J.P., Kraus D.H. First bite syndrome: incidence, risk factors, treatment, and outcomes. Laryngoscope 2012;122(8):1773–8. DOI: 10.1002/lary.23372

29. Blakaj A., Bonomi M., Gamez M.E., Blakaj D.M. Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data. Oral Oncol 2019;95:29–34. DOI: 10.1016/j.oraloncology.2019.05.013

30. Abuzarova G.R., Kosorukov V.S., Gamzeleva O.Yu. et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial. Onkologiya. Zhurnal im. P.A. Gercena = P.A. Herzen Journal of Oncology 2022;11(5):38–48. (In Russ.). DOI: 10.17116/onkolog20221105138

31. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: